Genetic markers of melanoma

Russian Journal of Genetics

Volumn 46, Issue 2, 2010, Pages 146-156

  Tronov, V A ^a   Artamonov, D N ^b   Gorbacheva, L B ^b  

^a SEMENOV INSTITUTE OF CHEMICAL PHYSICS   (Russian Federation)

^b EMANUEL INSTITUTE OF BIOCHEMICAL PHYSICS   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77749280166     PISSN: 10227954     EISSN: 16083369     Source Type: Journal    
DOI: 10.1134/S1022795410020031     Document Type: Article

References (105)

1. Miller, A. J. and Mihm, M. C., Mechanisms of Disease: Melanoma, N. Engl. J. Med., 2006, vol. 355, pp. 51-65.
2. Eigentler, T. and Garbe, C., Malignant Melanoma: Classification and Staging of Malignant Melanoma, Front. Radiat. Theor. Oncol., 2006, vol. 39, pp. 149-158.
3. McGovern, V. J., Cochran, A. J., van der Esch, E. P., et al., The Classification of Malignant Melanoma, Its Histological Reporting and Registration: A Revision of the 1972 Sydney Classification, Pathology, 1986, vol. 18, pp. 12-21.
4. McGovern, V. J., Mihm, M. C., Jr., Bailly, C., et al., The Classification of Malignant Melanoma and Its Histologic Reporting, Cancer, 1973, vol. 32, pp. 1446-1457.
5. Porras, B. H. and Cockerell, C. J., Cutaneous Malignant Melanoma: Classification and Clinical Diagnosis, Semin. Cutan. Med. Surg., 1997, vol. 16, pp. 88-96.
6. Balch, C. M., Soong, S. J., and Gershenwald, J., et al., Prognostic Factors Analysis of 17. 600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System, J. Clin. Oncol., 2001, vol. 19, pp. 3622-3634.
7. Halaban, R., Growth Factors and Melanomas, Semin. Oncol., 1996, vol. 23, pp. 673-681.
8. Recio, J. A., Noonan, F. P., Takayama, H., et al., Ink4a/Arf Deficiency Promotes Ultraviolet Radiation-Induced Melanomagenesis, Cancer Res., 2002, vol. 62, pp. 6724-6730.
9. Cui, R., Widlund, H. R., Feige, E., et al., Central Role of p53 in the Suntan Response and Pathologic Hyper-pigmentation, Cell, 2007, vol. 128, pp. 853-864.
10. Clark, W. H., Jr., Elder, D. E., Guerry, D. I., et al., Study of Tumor Progression: The Precursor Lesions of Superficial Spreading and Nodular Melanoma, Hum. Pathol., 1984, vol. 15, pp. 1147-1165.
11. Ramsey, M. R. and Sharpless, N. E., ROS as a Tumour Suppressor?, Nat. Cell Biol., 2006, vol. 8, pp. 1213-1215.
12. Ha, L., Merlino, G., and Sviderskaya, E. V., Melanomagenesis: Overcoming the Barrier of Melanocyte Senescence, Cell Cycle, 2008, vol. 7, pp. 1944-1948.
13. Clark, W. H., Jr, From, L., Bernardino, E. A., and Mihm, M. C., The Histogenesis and Biological Behavior of Primary Human Malignant Melanomas of the Skin, Cancer Res., 1969, vol. 29, pp. 705-727.
14. Hsu, M., Andl, T., Li, G., et al., Cadherin Repertoire Determines Partner-Specific Gap Junctional Communication during Melanoma Progression, J. Cell Sci., 2000, vol. 113, pp. 1535-1542.
15. Bennett, D. C. and Medrano, E. E., Molecular Regulation of Melanocyte Senescence, Pigment Cell Res., 2002, vol. 15, pp. 242-250.
16. Walker, G. J., Flores, J. F., Glendening, J. M., et al., Virtually 100% of Melanoma Cell Lines Harbor Alterations at the DNA Level within CDKN2A, CDKN2B, or One of Their Downstream Targets, Genes Chromosomes Cancer, 1998, vol. 22, pp. 157-163.
17. Ohta, M., Berd, D., Shimizu, M., et al., Deletion Mapping of Chromosome Region 9p2 l-p22 Surrounding the CDKN2 Locus in Melanoma, Int. J. Cancer, 1996, vol. 65, pp. 762-767.
18. Monzon, J., Liu, L., Brill, H., et al., CDKN2A Mutations in Multiple Primary Melanomas, N. Engl. J. Med., 1998, vol. 338, pp. 879-887.
19. Gonzalez-Gomes, P., Bello, M. J., Alonso, M. E., et al., Promoter Methylation Status of Multiple Genes in Brain Metastases of Solid Tumors, Int. J. Mol. Med., 2004, vol. 13, pp. 93-98.
20. Flores, J. F., Walker, G. J., Glendening, J. M., et al., Loss of the p16INK4a and p15INK4b Genes, as well as Neighboring 9p21 Markers, in Sporadic Melanoma, Cancer Res., 1996, vol. 56, pp. 5023-5032.
21. Ananthaswamy, H. N., Loughlin, S. M., and Cox, C., et al., Sunlight and Skin Cancer: Inhibition of p53 Mutations in UV-Irradiated Mouse Skin by Sunscreens, Nat. Med., 1997, vol. 3, pp. 510-514.
22. Costanzo, V, Robertson, K., Ying, C. Y., et al., Reconstitution of an ATMdependent Checkpoint That Inhibits Chromosomal DNA Replication Following DNA Damage, Mol. Cell, 2000, vol. 6, pp. 649-659.
23. Luca, M., Xie, S., Gutman, M., et al., Abnormalities in the CDKN2A (p16INK4/MTS-1) Gene in Human Melanoma Cells: Relevance to Tumor Growth and Metastasis, Oncogene, 1995, vol. 11, pp. 1399-1402.
24. Freedberg, D. E., Rigas, S. H., Russak, J., et al., Frequent pl6-Independent Inactivation of p14ARF in Human Melanoma, J. Natl. Cancer. Inst., 2008, vol. 100, no. 11, pp. 784-795.
25. Stahl, J. M., Cheung, M., Sharma, A., et al., Loss of PTEN Promotes Tumor Development in Malignant Melanoma, CancerRes., 2003, vol. 63, pp. 2881-2890.
26. Wu, H., Goel, V., and Haluska, F. G., PTEN Signaling Pathways in Melanoma, Oncogene, 2003, vol. 22, pp. 3113-3122.
27. Bartkova, J., Horejsi, Z., Koed, K., et al., DNA Damage Response as a Candidate Anti-Cancer Barrier in Early Human Tumorigenesis, Nature, 2005, vol. 434, pp. 864-870.
28. Lubbe, J., Reiche, M., Burg, G., and Kleihues, P., Absence of p53 Gene Mutations in Cutaneous Melanoma, J. Invest. Dermatol., 1994, vol. 102, pp. 819-821.
29. Papp, T., Jafari, M., and Schiffmann, D., Lack of p53 Mutations and Loss of Heterozygosity in Non-Cultured Human Melanocytic Lesions, J. Cancer Res. Clin. Oncol., 1996, vol. 122, pp. 541-548.
30. Spatz, A., Giglia-Mari, G., Benhamou, S., and Sarasin, A., Association between DNA-Repair Deficiency and High Level of P53 Mutations in Melanoma of Xeroderma Pigmentosum Patients, CancerRes., 2001, vol. 61, pp. 2480-2486.
31. Tornaletti, S. and Pfeifer, G. P., Slow Repair of Pyrim-idine Dimmers at p53 Mutation Hotspots in Skin Cancer, Science, 1994, vol. 263, pp. 1436-1438.
32. Davies, H., Bignell, G. R., Cox, C., et al., Mutations of the BRAF Gene in Human Cancer, Nature, 2002, vol. 417, pp. 949-954.
33. Pollock, P. M., Harper, U. L., Hansen, K. S., et al., High Frequency of BRAF Mutations in Nevi, Nat. Genet., 2003, vol. 33, pp. 19-20.
34. Wellbrock, C., Ogilvie, L., Hedley, D., et al., V599E5-RAF Is an Oncogene in Melanocytes, Cancer Res., 2004, vol. 64, pp. 2338-2342.
35. Hingorani, S. R., Jacobetz, M. A., Robertson, G. P., et al., Suppression of BRAF(V599E) in Human Melanoma Abrogates Transformation, Cancer Res., 2003, vol. 63, pp. 5198-5202.
36. Albino, A. P., Nanus, D. M., Mentle, I. R., et al., Analysis of ras Oncogenes in Malignant Melanoma and Precursor Lesions: Correlation of Pointmutations with Differentiation Phenotype, Oncogene, 1989, vol. 4, pp. 1363-1374.
37. Barbacid, M., Ras Genes, Annu. Rev. Biochem., 1987, vol. 56, pp. 779-827.
38. Demunter, A., Stas, M., Degreef, H., et al., Analysis of N- and K-ras Mutations in the Distinctive Tumor Progression Phases of Melanoma, J. Invest. Dermatol., 2001, vol. 117, pp. 1483-1489.
39. Whitwam, T., Vanbrocklin, M. W., Russo, M. E., et al., Differential Oncogenic Potential of Activated RAS Isoforms in Melanocytes, Oncogene, 2007, vol. 26, pp. 4563-4570.
40. Chin, L., Pomerantz, J., Polsky, D., et al., Cooperative Effects of INK4a and ras in Melanoma Susceptibility in vivo, Genes Dev., 1997, vol. 11, pp. 2822-2834.
41. Chin, L., Tam, A., Pomerantz, J., et al., Essential Role for Oncogenic ras in Tumour Maintenance, Nature, 1999, vol. 400, pp. 468-472.
42. Grichnik, J. M., Kit and Melanocyte Migration, J. Invest. Dermatol., 2006, vol. 126, pp. 945-947.
43. Widlund, H. R. and Fisher, D. E., Microphthalamia-Associated Transcription Factor: A Critical Regulator of Pigment Cell Development and Survival, Oncogene, 2003, vol. 22, pp. 3035-3041.
44. Alexeev, V. and Yoon, K., Distinctive Role of the cKit Receptor Tyrosine Kinase Signaling in Mammalian Melanocytes, J. Invest. Dermatol., 2006, vol. 126, pp. 1102-1110.
45. Curtin, J. A., Busam, K., Pinkel, D., et al., Somatic Activation of KIT in Distinct Subtypes of Melanoma, J. Clin. Oncol., 2006, vol. 24, pp. 4340-4346.
46. Seoane, J., Le, H. V. and Massagué, J., Myc Suppression of the p21(Cip1) Cdk Inhibitor Influences the Outcome of the p53 Response to DNA Damage, Nature, 2002, vol. 419, pp. 729-734.
47. Koynova, D., Jordanova, E., Kukutsch, N., et al., Increased C-MYC Copy Numbers on the Background of CDKN2A Loss Is Associated with Improved Survival in Nodular Melanoma, J. Cancer Res. Clin. Oncol. 2007, vol. 133, no. 2, pp. 117-123.
48. Bennett, D. C., Human Melanocyte Senescence and Melanoma Susceptibility Genes, Oncogene, 2003, vol. 22, pp. 3063-3069.
49. Petti, C., Molla, A., Vegetti, C., et al., Coexpression of NRASQ61R and BRAFV600E in Human Melanoma Cells Activates Senescence and Increases Susceptibility to Cell-Mediated Cytotoxicity, Cancer Res., 2006, vol. 66, pp. 6503-6511.
50. Zhuang, D., Mannava, S., and Grachtchouk, et. al., C-MYC Overexpression Is Required for Continuous Suppression of Oncogene-Induced Senescence in Melanoma Cells, Oncogene, 2008, vol. 27, no. 52, pp. 6623-6634.
51. Christmann, M., Tomicic, M. T., Aasland, D., and Kaina, B., A Role for UViight-Induced c-Fos: Stimulation of Nucleotide Excision Repair and Protection against Sustained JNK Activation and Apoptosis, Carcinogenesis, 2007, vol. 28, no. 1, pp. 183-190.
52. Bergman, R., Kerner, H., Manov, L., and Friedman-Birnbaum, R., C-Fos Protein Expression in Spitz Nevi, Common Melanocytic Nevi, and Malignant Melanomas, Am. J. Dermatopathol., 1998, vol. 20, no. 3, pp. 262-265.
53. Guang-Wu, H., Sunagawa, M., Jie-En, L., et al., The Relationship between Microvessel Density, the Expression of Vascular Endothelial Growth Factor (VEGF), and the Extension of Nasopharyngeal Carcinoma, Laryngoscope, 2000, vol. 110, pp. 2066-2069.
54. Dvorak, H. F., Brown, L. F., Detmar, M., and Dvorak, A. M., Vascular Permeability Factor/Vascular Endothelial Growth Factor, Microvascular Hypermeability, and Angiogenesis, Am. J. Pathol., 1995, vol. 146, pp. 1029-1039.
55. Yan, H., Marchettini, P., Acherman, Y. I., et al., Prognostic Assessment of Gastrointestinal Stromal Tumor, Am. J. Clin. Oncol., 2003, vol. 26, pp. 221-228.
56. Wan-Tzu Chen, Chih-Jen Huang, Ming-Tsang Wu, et al., HypoxiaJnducible Factor-la is Associated with Risk of Aggressive Behavior and Tumor Angiogenesis in Astrointestinal Stromal Tumor, Jpn. J. Clin. Oncol., 2005, vol. 35, no. 4, pp. 207-213.
57. Takeda, K., Takemoto, C., Kobayashi, I., et al., Ser298 of MITF, a Mutation Site in Waardenburg Syndrome Type 2, Is a Phosphorylation Site with Functional Significance, Hum. Mol. Genet., 2000, vol. 9, pp. 125-132.
58. Hodgkinson, C. A., Moore, K. J., Nakayama, A., et al., Mutations at the Mousemicrophthalmia Locus Are Associated with Defects in a Gene Encoding a Novel Basic-Helix-Loop-Helix-Zipper Protein, Cell, 1993, vol. 74, pp. 395-404.
59. Steingrimsson, E., Copeland, N. G., and Jenkins, N. A., Melanocytes and the Microphthalmia Transcription Factor Network, Ann. Rev. Genet., 2004, vol. 38, pp. 365-411.
60. Nishimura, E. K.., Granter, S. R., and Fisher, D. E., Mechanisms of Hair Graying: Incomplete Melanocyte Stem Cell Maintenance in the Niche, Science, 2005, vol. 307, pp. 720-724.
61. Garraway, L. A., Widlund, H. R., Rubin, M. A., et al., Integrative Genomic Analyses Identify MITF as a Lineage Survival Oncogene Amplified in Malignant Melanoma, Nature, 2005, vol. 436, no. 7, pp. 117-122.
62. Garraway, L. A. and Sellers, W. R., Lineage Dependency and Lineage-Survival Oncogenes in Human Cancer, Nat. Rev. Cancer, 2006, vol. 6, no. 8, pp. 593-602.
63. King, R., Weilbaecher, K. N., McGill, G., et al., Microphthalmia Transcription Factor: A Sensitive and Specific Melanocyte Marker for Melanoma Diagnosis, Am. J. Pathol., 1999, vol. 155, pp. 731-738.
64. Granter, S. R., Weilbaecher, K. N., Quigley, C., and Fisher, D. E., Role for Microphthalmia Transcription Factor in the Diagnosis of Metastatic Malignant Melanoma, Appl. Immunohistochem. Mol. Morphol., 2002, vol. 10, pp. 47-51.
65. Demunter, A., Libbrecht, L., Degreef, H., et al., Loss of Membranous Expression of Beta-Catenin Is Associated with Tumor Progression in Cutaneous Melanoma and Rarely Caused by Exon 3 Mutations, Mod. Pathol., 2002, vol. 15, pp. 454-461.
66. Omholt, K., Platz, A., Ringborg, U., and Hansson, J., Cytoplasmic and Nuclear Accumulation of Betacate-nin Is Rarely Caused by CTNNB1 Exon 3 Mutations in Cutaneous Malignant Melanoma, Int. J. Cancer, 2001, vol. 92, pp. 839-842.
67. Rubinfeld, B., Robbins, P., El-Gamil, M., et al., Stabilization of Beta-Catenin by Genetic Defects in Melanoma Cell Lines, Science, 1997, vol. 275, pp. 1790-1802.
68. Pollock, P. M. and Hayward, N., Mutations in Exon 3 of the Beta-Catenin Gene Are Rare in Melanoma Cell Lines, Melanoma Res., 2002, vol. 12, pp. 183-186.
69. Worm, J., Christensen, C., Gronb, K., et al., Genetic and Epigenetic Alterations of the APC Gene in Malignant Melanoma, Oncogene, 2004, vol. 23, pp. 5215-5226.
70. Castiglia, D., Bernardini, S., Alvino, E., et al., Concomitant Activation of Wnt Pathway and Loss of Mismatch Repair Function in Human Melanoma, Genes Chromosomes Cancer, 2008, vol. 47, pp. 614-624.
71. Trauth, B. C., Klas, C., Peter, A. M., etal., Monoclonal Antibody-Mediated Tumor Regression by Induction of Apoptosis, Science, 1989, vol. 245, pp. 301-305.
72. Tanaka, M., Suda, T., Takahashi, T., and Nagata, S., Expression of the Functional Soluble Form of Human Fas Ligand in Activated Lymphocytes, EMBOJ., 1995, vol. 14, pp. 1129-1135.
73. Schneider, P., Holler, N., Bodmer, J. L., et al., Conversion of Membrane-Bound Fas(CD95) Ligand to Its Soluble Form Is Associated with Downregulation of Its Proapoptotic Activity and Loss of Liver Toxicity, J. Exp. Med., 1998, vol. 187, pp. 1205-1213.
74. Peter, M. E. and Krammer, PH., The CD95 (APO-1/Fas) DISC and Beyond, Cell Death Differ., 2003, vol. 10, pp. 26-35.
75. Fulda, S., Sieverts, H., Friesen, C., et al., The CD95 (APO-LIFas) System Mediates Drug-Induced Apoptosis in Neuroblastoma Cells, Cancer Res., 1997, vol. 57, pp. 3823-3829.
76. Friesen, C, Herr, I., Krammer, PH., and Debatin, K-M., Involvement of the CD95 (APO-L/Fas) Receptor-Ligand System in Drug-Induced Apoptosis in Leukemia Cells, Nat. Med., 1996, vol. 2, pp. 574-577.
77. Ivanov, V. N., Ronai, Z., and Hei, T. K., Opposite Roles of FAP-1 and Dynamin in the Regulation of Fas (CD95) Translocation to the Cell Surface and Susceptibility to Fas Ligand-Mediated Apoptosis, J. Biol. Chem., 2006, vol. 281, pp. 1840-1852.
78. Jackson, C. E. and Puck, J. M., Autoimmune Lym-phoproliferative Syndrome, a Disorder of Apoptosis, Curr. Opin. Pediatr., 1999, vol. 11, pp. 521-527.
79. Fuchs, H., Posovszky, C., Lahr, G., et al., Residual CD95-Pathway Function in Children with Autoimmune Lymphoproliferative Syndrome Is Independent from Clinical State and Genotype of CD95 Mutation, Pediatr. Res., 2009, vol. 65, pp. 163-168.
80. Min Sun Shin, Won Sang Park, Su Young Kim, et al., Alterations of Fas (Apo-1/CD95) Gene in Cutaneous Malignant Melanoma, Am. J. Pathol., 1999, vol. 154, pp. 1785-1791.
81. Peter, M. E., Legembre, P., and Barnhart, B. C., Does CD95 Have Tumor Promoting Activities?, Biochim. Biophys. Acta, 2007, vol. 1775, pp. 233-234.
82. Legembre, P., Barnhart, B. C., Zheng, L., et al., Induction of Apoptosis and Activation of NF-kB by CD95 Require Different Signalling Thresholds, EMBO Reports, 2004, vol. 5, pp. 1084-1089.
83. Song, H. Y., Regnier, C. H., Kirschning, C. J., et al., Tumor Necrosis Factor (TNF)-Mediated Kinase Cascades: Bifurcation of Nuclear Factor Kappa B and c-jun N-Terminal Kinase (JNK/SAPK) Pathways at TNF Receptor-Associated Factor 2, Proc. Natl. Acad. Sci. USA, 1997, vol. 94, pp. 9792-9796.
84. Arczewska, K. D. and Kusmierek, J. T., Bacterial DNA Repair Genes and Their Eukaryotic Homologues: 2. Role of Bacterial Mutator Gene Homologues in Human Disease. Overview of Nucleotide Pool Sanitization and Mismatch Repair Systems, Acta. Biochim. Pol., 2007, vol. 54, pp. 435-457.
85. Tronov, V. A., Kramarenko, I. I., and Karpukhin, A. V., Colorectal Cancer: Repair Deficiency, Genome Instability, Resistance to Apoptosis, Evaluation of the Disease Risk, Vopr. Onkol., 2005, vol. 52, pp. 159-166.
86. Franchitto, A., Pichierri, P., Piergentili, R., et al., The Mammalian Mismatch Repair Protein MSH2 is Required for Correct MRE1 1 and RAD51 Relocaliza-tion and for Efficient Cell Cycle Arrest Induced by Ionizing Radiation in G2 Phase, Oncogene, 2003, vol. 22, pp. 2110-2120.
87. Mohindra, A., Hays, L. E., Phillips, E. N., et al., Defects in Homologous Recombination Repair in Mismatch-Repair-Deficient Tumor Cell Lines, Hum. Mol. Genet., 2002, vol. 11, pp. 2189-2200.
88. Xuan, Li. and Heyer, W.-D., Homologous Recombination in DNA Repair and DNA Damage Tolerance, Cell Res., 2008, vol. 18, pp. 99-113.
89. Bignami, M., Os'Driscoll, M., Aquilina, G., and Karran, P., Unmasking a Killer: DNA O6-Methylguanine and the Cytotoxicity of Methylating Agents, Mutat. Res., 2000, vol. 462, pp. 71-82.
90. Ochs, K. and Kaina, B., Apoptosis Induced by DNA Damage O6-Methylguanine Is Bcl-2 and Caspase-9/3 Regulated and Fas/Caspase-8 Independent, Cancer Res., 2000, vol. 60, pp. 5815-5824.
91. Tronov, V. A., Loginova, M. Yu., and Kramarenko, I. I., Methylnitrosourea as Challenge Mutagen in Assessment of the DNA Mismatch Repair (MMR) Activity: Association with some Types of Cancer, Russ. J. Genet., 2008, vol. 44, pp. 595-600.
92. Ma, S., Egyhcozi, S., Ringborg, U., and Hansson, J., Immunohistochemical Analysis of DNA Mismatch Repair Protein and O6-Methylguanine-DNA Meth-yltransferase in Melanoma Metastases in Relation to Clinical Response to DTIC-Based Chemotherapy, Oncol. Rep., 2002, vol. 9, pp. 1015-1019.
93. Shpitz, B., Klein, E., Malinger, P., et al., Altered Expression of the DNA Mismatch Repair Proteins hMLH1 and hMSH2 in Cutaneous Dysplastic Nevi and Malignant Melanoma, Int. J. Biol. Markers, 2005, vol. 20, pp. 65-68.
94. Garcia, J. J., Kramer, M. J., Os'Donnell, R. J., and Horvai, A. E., Mismatch Repair Protein Expression and Microsatellite Instability: A Comparison of Clear Cell Sarcoma of Soft Parts and Metastatic Melanoma, Mod. Pathol., 2006, vol. 19, pp. 950-957.
95. Kohonen-Corish, M. R. J., Cooper, W. A., Saab, J., et al., Promoter Hypermethylation of the O6-Meth-ylguanine DNA Methyltransferase Gene and Microsatellite Instability in Metastatic Melanoma, J. Inves-tig. Dermat., 2006, vol. 126, pp. 167-171.
96. Yoshimoto, Y., Augustine, C. K., Yoo, J. S., et al., Defining Regional Infusion Treatment Strategies for Extremity Melanoma: Comparative Analysis of Mel-phalan and Temozolomide as Regional Chemothera-peutic Agents, Mol. Cancer Ther., 2007, vol. 6, pp. 1492-500.
97. Naumann, S. C., Roos, W. P., Jost, E., et al., Temozolomide- and Fotemustine-Induced Apoptosis in Human Malignant Melanoma Cells: Response Related to MGMT, MMR, DSBs, and p53, British J. Cancer, 2009, vol. 100, pp. 322-333.
98. Beranek, D. T., Distribution of Methyl and Ethyl Adducts Following Alkylation with Monofunctional Alkylating Agents, Mutat. Res., 1990, vol. 231, pp. 11-30.
99. Sobol, R. W, Watson, D. E., Nakamura, J., et al., Mutations Associated with Base Excision Repair Deficiency and Methylation-Induced Genotoxic Stress, Proc. Natl. Acad. Sci. USA, 2002, vol. 99, pp. 6860-6865.
100. Trivedi, R. N., Almeida, K. H., Fornsaglio, J. L., et al., The Role of Base Excision Repair in the Sensitivity and Resistance to Temozolomide-Mediated Cell Death, Cancer Res., 2005, vol. 65, pp. 6394-6400.
101. Liu, L., Taverna, P., Whitacre, CM., et al., Pharmacologic Disruption of Base Excision Repair Sensitizes Mismatch Repair-Deficient and- Proficient Colon Cancer Cells to Methylating Agents, Clin. Cancer Res., 1999, vol. 5, pp. 2908-2917.
102. Bucci, B., D'Agnano, I., Amendola, D., et al., Myc Down-Regulation Sensitizes Melanoma Cells to Radiotherapy by Inhibiting MLH1 and MSH2 Mismatch Repair Proteins, Clin. Cancer Res., 2005, vol. 11, pp. 2756-2767.
103. Nadin, S. B., Vargas-Roig, L. M., Drago, G., et al., DNA Damage and Repair in Peripheral Blood Lymphocytes from Healthy Individuals and Cancer Patients: A Pilot Study on the Implications in the Clinical Response to Chemotherapy, Cancer Lett., 2006, vol. 239, pp. 84-97.
104. Tronov, V. A., Kramarenko, I. I., Kozlova, A. D., et al., Sensitivity of Human Lymphocytes to Genotoxic Effect of N-Methyl-N-Nitrosourea: Possible Relation to Gynecological Cancers, Exp. Oncol., 2006, vol. 28, pp. 1-4.
105. Tarasov, V. A., Aslanyan, M. M., Tsyrendorzhieva, E. S., et al., Population Genetic Analysis of the Association between the BRCA1 and P53 Gene Polymorphisms and the Risk of Sporadic Breast Cancer, Russ. J. Genet., 2005, vol. 41, pp. 1115-1124.